AMAG: Summary for AMAG Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 4:14am EST - Canadian Markets open in 5 hours and 16 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

AMAG Pharmaceuticals, Inc. (AMAG)

On Feb 9: 36.08 USD 0.00 (0.00%)

MORE ON AMAG

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

AMAG Pharmaceuticals, Inc. (NGM:AMAG) Delayed quote data

Last Trade:	36.08 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	36.08
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	58.13

Day's Range:	N/A - N/A
52wk Range:	22.20 - 58.23
Volume:	0
Avg Vol (3m):	736,722
Market Cap:	618.16M
P/E (ttm):	N/A
EPS (ttm):	-5.67
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add AMAG to Portfolio

Download Data

HEADLINES

•	Early-Market Movers: China Agritech, Novavax Inc
	at Fox Business (Mon, Feb 8)

•	AMAG Defends Feraheme Safety: BioBuzz
	at TheStreet.com (Mon, Feb 8)

•	UPDATE - AMAG safety update on anemia drug lifts shares
	at Reuters (Fri, Feb 5)

•	AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Fri, Feb 5)

•	AMAG Pharmaceuticals Provides Feraheme® Safety Update
	Business Wire (Fri, Feb 5)

•	Iron Safety Hits AMAG Pharmaceuticals
	at Seeking Alpha (Thu, Feb 4)

•	Thursday Options Update: GFI, SU, MA, ZION, DAL, AMAG & JWN
	at Seeking Alpha (Thu, Feb 4)

•	AMAG Pharma Tumbles on Feraheme Safety Concerns: BioBuzz
	at TheStreet.com (Thu, Feb 4)

•	Recent Dividend Hikes May Point to a Return to Normalcy
	at Seeking Alpha (Sun, Jan 24)

•	AMAG Pharma prices, expands stock offering
	at bizjournals.com (Thu, Jan 21)

•	Amag Pharmaceuticals prices 3.6M stock offering
	AP (Thu, Jan 21)

•	AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
	EDGAR Online (Thu, Jan 21)

•	AMAG Pharmaceuticals Announces Pricing of Public Offering of 3,600,000 Shares of Common Stock
	Business Wire (Wed, Jan 20)

More Headlines for AMAG...

ANALYST

EPS Est (next year) (Dec-09) :	-5.48
EPS Est (in 2 years) (Dec-10) :	-2.59
Avg Rec (current)*:	1.8
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan.

Full Company Profile

Add to Portfolio

Email to a Friend

•